Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Home About Us My Account Personal Library Customer Service    
Welcome Guest
(login/register)
US: 800.298.5699
Int'l: +1.240.747.3093
Quick Search
Advanced Search >
Research Assistance
Send us a request >
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
Home > Back to Publisher > Report Information Email a colleague | Printer format

Melanoma Drug Pipeline Update 2009

BioSeeker Group AB
January 20, 2009
- Pub ID: BIOS2108745
 
Questions about this report >
Order by fax >
XE.com
Abstract

Table of
Contents
Related Reports


Executive Summary

Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.

There are today more than 200 therapeutics targeting melanoma in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years amount to another 82 drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 143 different targets. These targets are further categorized on the CD-ROM by 47 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Melanoma Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

Show investors/board/management that you are right on top of drug development progress in your therapeutic area. Find competitors, collaborations partners, M&A candidates etc. Jump start competitive drug intelligence operations Excellent starting point for world wide benchmarking Compare portfolio and therapy focus with your peers Speed up pro-active in-/out licensing strategy work Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements below.

Drug Pipeline Update at a Glance

Investigators Includes 191 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.

Drug name & Synonyms Lists commercial, generic and code names for drugs. In all more than 300 names

Developmental stage This Drug Pipeline Update contains more than 204 drugs in active development for the treatment of melanoma:
#13 marketed drugs
#2 drug registered
#3 drugs in pre-registration
#8 drugs in Phase III
#81 drugs in Phase II
#50 drugs in Phase I
#41 drugs in Preclinical
#6 drugs in other developmental stages
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications Included melanoma drugs are also in development for over 110 other indications. Note: You are able to sort and find drugs according to type of indication from drop-down menu in the application.

Targets Identified drugs are linked to more than 143 different targets, divided into 47 classifications of molecular function:
  • Carboxylyase activity
  • Catalytic activity
  • Cell adhesion molecule activity
  • Chaperone activity
  • Chemokine activity
  • Cofactor binding
  • Complement activity
  • Cytokine activity
  • DNA binding
  • DNA repair protein
  • DNA topoisomerase activity
  • DNAdirected DNA polymerase activity
  • DNAmethyltransferase activity
  • Extracellular ligandgated ion channel activity
  • Extracellular matrix structural constituent
  • Gprotein coupled receptor activity
  • Growth factor activity
  • Hydrolase activity
  • Isomerase activity
  • Kinase activity
  • Kinase regulator activity
  • Ligase activity
  • Lipase activity
  • MHC class I receptor activity
  • Molecular function unknown
  • Motor activity
  • Oxidoreductase activity
  • Protein binding
  • Protein serine/threonine kinase activity
  • Protein threonine/tyrosine kinase activity
  • Protein tyrosine phosphatase activity
  • Proteintyrosine kinase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • RNAdirected DNA polymerase activity
  • Serinetype peptidase activity
  • Structural constituent of cytoskeleton
  • Superoxide dismutase activity
  • T cell receptor activity
  • Transcription factor activity
  • Transcription regulator activity
  • Transferase activity
  • Translation regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Transporter activity
  • Identified targets are categorized into 19 different primary and alternate sub
  • cellular localizations:
  • Cell surface
  • Centrosome
  • Clathrincoated vesicle
  • Cytoplasm
  • Cytoplasmic vesicle
  • Cytoskeleton
  • Endoplasmic reticulum
  • Endosome
  • Extracellular
  • Golgi apparatus
  • Lysosome
  • Mitochondrion
  • Nucleolus
  • Nucleus
  • Perinuclear vesicle
  • Peroxisome
  • Plasma membrane
  • Secreted
  • Secretory vesicle
Note: You are able to sort and find drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.

Target Expression Profile Direct links are provided from inside the application to 150 protein expression profiles of 103 drug targets in various human tissues and cancer types, cell lines and primary cells, includin up to:
    48 different normal tissue types 20 different types of cancer 47 cell lines 12 samples of primary blood cells Pathway Referals Identified targets have been cross referenced against their invovlement in different cellular pathways, according to BioCarta, KEGG and NetPath. BioCarta 202 Pathways KEGG 74 Pathways NetPath 18 Signaling Pathways
Note: You are able to sort and find drugs according to targeted pathways from drop-down menues in the application.

Mechanism In total there are 161 different drug mechanism of action represented in this Drug Pipeline Update. Note: You are able to sort and find drugs according to mechanism of action from drop-down menu in the application.

Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application. Drug Profile Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information: Drug Name & Synonyms Presentation of drug name and synonyms

Principal Investigator & Partners Presentation of principal investigator and partners

Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol - Official Gene Name [Species/Homo Sapiens] - Molecular Function

Target Localization Described target(s) is/are presented with primary and alternate localizations.

Target Expression Profiles Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.

Mechanism Drug mechanism of action

Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status. Example: Cancer, myeloma - Phase II Clinical Trial - Active Cancer, prostate - Phase III Clinical Trial - Ceased

Drug Description Short introduction to drug

Compound Data Compound type, Chemical name, CAS Number and molecular weight

Patent Data Available patent information related to the drug is presented here.

Business & Markets Collaborations and deals Approvals and submissions Analyst comments

Phase III Data Available Phase III development data, developmental history and scientific data.

Phase II Data Available Phase II development data, developmental history and scientific data.

Phase I Data Available Phase I development data, developmental history and scientific data.

Preclinical Data Available preclinical development data, developmental history and scientific data.

Licensing Information Availability for licensing

Application Features Use 13 different parameters, available in drop-down menus, to find and sort among drugs
  • Drug status
  • Clinical Trial Status
  • Principle Investigator
  • Partners
  • Indication
  • Developmental Stage
  • Compound Type
  • Mechanism
  • Target
  • Molecular Function of Target
  • Target Localization
  • Targeted Pathways
  • Free text search of entire drug profile contents
  • Direct linkage from inside the application to related internet resources
  • Drug data is linked to search engines like Google and PubMed
  • Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
  • Direct links to company web pages of principal investigators
  • Export and sharing of information
  • Found information is easily shared with others over e
  • mail, file export (xls) or in print

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Competitor Analysis: TGF-R Agonists and Antagonists
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Strategic Analysis of the Bladder Cancer Therapeutics
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report

Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 4